Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status

Journal of the Formosan Medical Association

Volumn 104, Issue 8, 2005, Pages 557-562

  Su, Wen Pin ^a   Yang, Chih Hsin ^a,b   Yu, Chong Jen ^a   Shih, Jin Yuan ^a   Hsu, Chiun ^a,b   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gefitinib; Non small cell lung carcinoma; Performance status; Treatment outcome

Indexed keywords

CISPLATIN; GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRY SKIN; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NAUSEA; PRURITUS; RASH; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 27744545400     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schiller J: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61(Suppl 1):3-13.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
3. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
4. Fry DW: Site-directed irreversible inhibitors of Erb-B family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Res 2000;15:3-16.
5. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
6. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer (NSCLC) patients: A randomized trial. JAMA 2003;290:2149-58.
7. Therasse P: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
8. Huisman C, Smit EF, Giaccone G, et al: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000;18:3722-30.
9. Park J, Park BB, Kim JY, et al: Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8.
10. Takano T, Ohe Y, Kusumoto M, et al: Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer with gefitinib. Lung Cancer 2004;45:93-104.
11. Chiu CH, Tsai-CM, Chen YM, et al: Gefitinib is active in patients with brain metastasis from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47:129-38.
12. Paez JG, Janne PA, Lee JC, et al: EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
13. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
14. Miller VA, Kris MG, Shah N, et al: Bronchoalveolar pathological subtype and smoking history predict sensitivity to gefinitib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.